In a study of persons with moderate-to-severe atopic dermatitis, lebrikizumab monotherapy for 16 weeks resulted in improved quality of life and mental health.
In a study of adolescents with obesity, symptoms of depression and eating disorders decreased over the course of a 52-week intensive behavioral intervention.